Sprout Pharmaceuticals Announces Release of Abstract Reporting Positive Interim Results for Flibanserin in Breast Cancer Patients Suffering from Low Libido for Poster Discussion at 2023 ASCO Annual Meeting

70% of women diagnosed with breast cancer report having sexual dysfunction, this includes disorders of sexual desire and sexual response. RALEIGH, N.C., June 2, 2023 /PRNewswire/ — Sprout Pharmaceuticals, Inc. a pharmaceutical company specializing in women’s sexual health today announced publication of abstract 12015 by the American Society of Clinical Oncology (ASCO). The abstract reporting … Read more